TI
FATE icon

Trexquant Investment’s Fate Therapeutics FATE Stock Holding History

Trexquant Investment’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-257,716
Closed -$1.89M – 1611
2024
Q1 		$1.89M Buy
+257,716
New +$1.6M 0.04% 678
2023
Q3 		– Sell
-333,986
Closed -$1.59M – 1564
2023
Q2 		$1.59M Sell
333,986
-31,400
-9% -$173K 0.04% 583
2023
Q1 		$2.08M Buy
365,386
+173,449
+90% +$1.05M 0.06% 445
2022
Q4 		$1.94M Buy
191,937
+129,049
+205% +$2.42M 0.05% 418
2022
Q3 		$1.41M Buy
62,888
+54,168
+621% +$1.57M 0.05% 436
2022
Q2 		$216K Buy
+8,720
New +$241K 0.01% 1313
2021
Q4 		– Sell
-15,428
Closed -$914K – 1395
2021
Q3 		$914K Buy
+15,428
New +$1.21M 0.07% 345
2021
Q2 		– Sell
-13,516
Closed -$1.11M – 1212
2021
Q1 		$1.11M Buy
13,516
+2,461
+22% +$236K 0.1% 251
2020
Q4 		$1M Buy
+11,055
New +$687K 0.11% 256
2020
Q1 		– Sell
-33,373
Closed -$653K – 1208
2019
Q4 		$653K Buy
+33,373
New +$530K 0.04% 484
2018
Q2 		– Sell
-18,369
Closed -$179K – 980
2018
Q1 		$179K Buy
+18,369
New +$176K 0.01% 963

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Trexquant Investment's FATE Position: Q2 2024 in Review

Trexquant Investment sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 257,716 shares — an estimated $1.89M sold.

Trexquant Investment first reported a position in FATE in Q1 2018 and held it in 11 quarters. The position peaked at $2.08M in Q1 2023. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Trexquant Investment reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Trexquant Investment sold 257,716 Fate Therapeutics shares in Q2 2024, an estimated $1.89M.
  • Trexquant Investment first reported a position in Fate Therapeutics in Q1 2018 and held it in 11 quarters.
  • Trexquant Investment's Fate Therapeutics position peaked at $2.08M in Q1 2023.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Trexquant Investment's 13F filing for Q2 2024, filed 13 Aug 2024.